Recent Updates
Recently added Catalysts
HNGE Positive Sentiment

Hinge Health reports record second quarter 2026 financial results; signs definitive agreement to acquire Cylinder Health

Tuesday, August 4, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Hinge Health, Inc. reported impressive financial results for the second quarter of 2026, achieving $213 million in revenue, which marks a 53% increase year-over-year. The company also tripled its free cash flow compared to the previous year. Additionally, Hinge Health announced a definitive agreement to acquire Cylinder Health, further expanding its business operations.

Market Sentiment Analysis

POSITIVE FACTORS

  • Record revenue of $213 million in Q2 2026.
  • 53% year-over-year growth in revenue.
  • Tripled free cash flow compared to last year.
  • Strong member conversion rates.

Full Press Release Details

SAN FRANCISCO--(BUSINESS WIRE)--Hinge Health, Inc. (NYSE: HNGE) today announced financial results for the second quarter ended June 30, 2026 and provided a business update. “We delivered another strong quarter ahead of expectations, generating $213 million in revenue with 53% year-over-year growth, while more than tripling free cash flow from a year ago. This quarter’s outperformance was driven by continued high member conversion and reflects our ability to deliver a great experience, improve m

Frequently Asked Questions

What were Hinge Health's Q2 2026 revenue figures?

Hinge Health reported $213 million in revenue for Q2 2026.

How much did Hinge Health's revenue grow year-over-year?

The company experienced a 53% year-over-year revenue growth.

What significant acquisition did Hinge Health announce?

Hinge Health announced a definitive agreement to acquire Cylinder Health.

How did Hinge Health's free cash flow change?

Hinge Health tripled its free cash flow compared to the previous year.

ShareAdd on Google
Tags: HNGE Viatris Investor Conferences Healthcare Hinge Health Cylinder Health financial results acquisition
Last updated: Aug 4, 2026

Biotech snapshot

Cash runway
$316M liquidity · $0M/mo burn
Low dilution risk